{'fraction_non_alphanumeric': 0.03253182461103253, 'fraction_numerical': 0.0, 'mean_word_length': 4.851239669421488, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Stent thrombosis redux--the FDA perspective.

Stent Thrombosis Redux — The FDA Perspective Dr. Andrew Farb and Ashley Boam write that as compared with on-label use, off-label use of drug-eluting stents is associated with increased risks of both early and late stent thrombosis, as well as death or myocardial infarction. Given the benefits and risks, physicians should consider certain patient characteristics in deciding whether to use a drug-eluting or a bare-metal stent. Dr. Donald Baim, chief medical and scientific officer of Boston Scientific, and Dr. Steven Nissen, chairman of The Department of Cardiovascular Medicine at The Cleveland Clinic, discuss the risks and benefits of drug-eluting stents.